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Abstract
Burkholderia gladioli is a bacterium with a broad ecology spanning disease in humans, animals and plants, but also encompass-
ing multiple beneficial interactions. It is a plant pathogen, a toxin- producing food- poisoning agent, and causes lung infections in 
people with cystic fibrosis (CF). Contrasting beneficial traits include antifungal production exploited by insects to protect their 
eggs, plant protective abilities and antibiotic biosynthesis. We explored the genomic diversity and specialized metabolic poten-
tial of 206 B. gladioli strains, phylogenomically defining 5 clades. Historical disease pathovars (pv.) B. gladioli pv. allicola and 
B. gladioli pv. cocovenenans were distinct, while B. gladioli pv. gladioli and B. gladioli pv. agaricicola were indistinguishable; soft- rot 
disease and CF infection were conserved across all pathovars. Biosynthetic gene clusters (BGCs) for toxoflavin, caryoynencin 
and enacyloxin were dispersed across B. gladioli, but bongkrekic acid and gladiolin production were clade- specific. Strikingly, 
13 % of CF infection strains characterized were bongkrekic acid- positive, uniquely linking this food- poisoning toxin to this 
aspect of B. gladioli disease. Mapping the population biology and metabolite production of B. gladioli has shed light on its diverse 
ecology, and by demonstrating that the antibiotic trimethoprim suppresses bongkrekic acid production, a potential therapeutic 
strategy to minimize poisoning risk in CF has been identified.
DATA SUMMARY
Burkholderia gladioli genome sequences determined as part 
of this study are deposited under BioProjects PRJEB35318 
and PRJEB9765. Complete genomes are available for 4 strains 
(BCC1622, GCA_900608515; BCC1621, GCA_900608525; 
BCC1710, GCA_900608535; BCC0238, GCA_900631635.1) 
and 206 draft genomes were determined with the accession 
numbers provided in Table S1 (available in the online version 
of this article).
INTRODUCTION
The genus Burkholderia contains important plant, animal 
and human pathogenic bacteria [1, 2], as well as environ-




Jones et al., Microbial Genomics 2021;7:000515
nucleotide- based analyses have split Burkholderia strains 
into distinct lineages corresponding to Burkholderia sensu 
stricto, Paraburkholderia, Caballeronia, Robbsia, Trinickia 
and Mycetohabitans [4]. Within Burkholderia sensu stricto, 
the Burkholderia cepacia complex group of species are prob-
lematic lung pathogens in people with cystic fibrosis (CF) 
[2]. The three most commonly isolated Burkholderia species 
among US CF patients are B. multivorans, B. cenocepacia 
and, interestingly, B. gladioli [2]. Although phenotypically 
similar, genetically B. gladioli is not a member of the B. cepacia 
complex, but is part of a group of species associated with plant 
disease, including B. glumae and B. plantarii [3]. In relation to 
CF infection, B. gladioli may cause severe systemic abscesses 
[5] and is also considered a risk factor for lung transplantation, 
since it is associated with poor clinical outcome [6]. While 
the potential for patient- to- patient spread and rapid clinical 
decline are identified traits of B. cepacia complex infection 
in people with CF [2], the population biology, epidemiology 
and genomics of B. gladioli as a lung pathogen are essentially 
unknown.
In relation to its environmental ecology, B. gladioli was 
originally isolated as a pathogen of the flowering plant genus 
Gladiolus and its taxonomy has been updated several times 
[7]. The current species encompasses the historical Gladiolus 
disease causing taxa Pseudomonas gladioli and Pseudomonas 
marginata [8], the food poisoning- associated B. cocovenenans 
[7], and the potential biological control agent Pseudomonas 
antimicrobica [9]. B. gladioli has also been isolated as a 
pathogen of important crops that resulted in pathovar 
(pv.) designations being applied to the causative isolates of: 
mushroom rot, B. gladioli pv. agaricicola [10]; onion rot, 
B. gladioli pv. allicola [11]; and the historical bulb rot disease, 
B. gladioli pv. gladioli [8]. B. gladioli and its close relative 
B. glumae are also major rice pathogens causing panicle blight 
[12]. B. cocovenenans represents a fourth pathovar [13] that 
is responsible for food poisoning when tempe bongkrek, 
the fermented coconut- based Indonesian national dish, 
is produced with Rhizopus fungal cultures contaminated 
with B. gladioli [14]. Under these conditions, a polyketide 
biosynthetic gene cluster (BGC) is activated in B. gladioli pv. 
cocovenenans that directs the production of the respiratory 
toxin bongkrekic acid, which is fatal when ingested [14]. The 
B. gladioli pathovars had been assigned based on the source 
of isolates and researchers have argued that there is a need 
to differentiate the lethal toxin- producing pathovars such as 
B. gladioli pv. cocovenenans [13]. However, the evolutionary 
basis of the pathovar designations of B. gladioli remains to be 
systematically investigated.
The capacity to produce a diverse range of specialized metab-
olites ranging from toxins such as bongkrekic acid [14] to 
beneficial antibiotics is a common trait among Burkholderia 
bacteria [1, 15]. Close ecological associations with multiple 
eukaryotic hosts is a key primer for metabolite production 
by B. gladioli. As a detrimental trait, it produces toxoflavin a 
yellow phytotoxin that enhances the virulence of B. gladioli 
in rice disease [16]. In addition to bongkrekic acid, B. gladioli 
produces the polyketide antibiotic enacyloxin IIa in co- culture 
with the fungus Rhizopus microspores [17]. A close association 
of B. gladioli with fungi was linked to the discovery that the 
bacterium contains a gene encoding a nonribosomal peptide 
synthetase (NRPS) that assembles icosalide A1, a metabolite 
originally characterized as a product of an Aureobasidium 
fungus [18, 19]. PCR screening of DNA extracts from the 
original Aureobasidium culture demonstrated that a B. gladioli 
symbiont containing the icosalide NRPS gene was present 
[19]. The vertical transmission of symbiotic B. gladioli in 
herbivorous Lagriinae beetles clearly demonstrates how 
ecological benefit may derive from the metabolites the bacte-
rium produces [20]. B. gladioli was found in the reproduc-
tive tract of the beetles and produced several antimicrobial 
metabolites, including toxoflavin, caryoynencin, lagriene 
(iso- gladiolin [21]) and sinapigladioside, which protected 
the Lagriinae eggs from fungal attack [20].
Genomics has revolutionized our understanding of Burk-
holderia population biology, and the beneficial and detri-
mental interactions of these ecologically diverse bacteria. 
Insights into the biosynthesis of gladiolin, a novel polyketide 
antibiotic with promising activity against Mycobacterium 
tuberculosis, were facilitated by complete genome sequencing 
of B. gladioli BCC0238 [21]. Using a combination of system-
atic approaches, including genome mining for specialized 
metabolite BGCs, metabolite characterization and phenotypic 
Impact Statement
Burkholderia gladioli is a fascinating bacterium with 
detrimental traits of plant pathogenicity, food- poisoning 
toxicity and the ability to cause lung infections in people 
with cystic fibrosis (CF). In contrast, because B. gladioli 
can produce multiple antimicrobial specialized metabo-
lites, it can protect insects and plants, and has been 
recently exploited as an antibiotic producer. To under-
stand the genomic and metabolic basis of this diversity, 
we genome- sequenced a collection of 206 B. gladioli 
isolates, and examined the specialized metabolites they 
encode and produce. While all agriculturally defined 
B. gladioli disease pathovars (pv.) were found to repre-
sent a single species, B. gladioli pv. allicola and B. gladioli 
pv. cocovenenans were evolutionarily distinct. In addition, 
the latter food- poisoning strains were unified as a group 
because they all encoded the potent toxin bongkrekic 
acid. Worryingly, 13 % of B. gladioli recovered from CF 
lung infection also encoded the toxin and could produce 
bongkrekic acid when grown in conditions mimicking CF 
sputum. Although identification of toxin- positive strains 
represents a potential new risk factor for CF, we showed 
that the clinically used antibiotic trimethoprim was 
able to suppress toxin bongkrekic acid production. Our 
genomic and metabolic analysis of B. gladioli has broad 
impacts for agriculture, biotechnology, chemistry and 
medicine.
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assays, production of the antimicrobial cepacin was shown 
to underpin biological control of damping- off disease by the 
biopesticide species Burkholderia ambifaria [22]. However, a 
limited number of complete genome sequences are available 
for B. gladioli, including strain BSR3, a rice disease isolate 
[23], the bulb- associated type strain ATCC 10248 [24], and 
the CF lung infection isolate, BCC0238 [21]. Here we inves-
tigate the population biology of B. gladioli as a functionally 
diverse species that interacts with human, plant, insect and 
microbial ecosystems. Using genome sequence analysis of 
206 B. gladioli strains from diverse sources, we defined the 
genetic linkage to pathovar status, mapped the ability to 
mediate plant soft- rot and human disease, and correlated 
population biology to capacity for specialized metabo-
lite production. The genomics- based taxonomy of all the 
B. gladioli isolates was consistent with their designation as a 
single species. Pathovars B. gladioli pv. allicola and B. gladioli 
pv. cocovenenans, as well as BGCs for bongkrekic acid and 
gladiolin, were shown to be clade- restricted within the overall 
B. gladioli population. People with CF were susceptible to all 
clades of B. gladioli and the presence of the bongkrekic acid 
BGC was revealed as a new risk factor for these infectious 
isolates.
METHODS
Bacterial strains and growth conditions
A collection of 206 B. gladioli isolates was assembled for 
this study and their source details, genomic features and the 
analysis they were subject to are included in the Supplemen-
tary Material (Table S1). These were drawn from the Cardiff 
collection [21, 22, 25] and the Burkholderia cepacia Research 
Laboratory and Repository (University of Michigan, MI, 
USA) [2], with additional reference and pathovar strains of 
B. gladioli obtained from the Belgium Coordinated Collection 
of Microorganisms (Ghent, Belgium) and National Collec-
tions of Plant Pathogenic Bacteria (York, UK) (Table S1). 
B. gladioli isolates were routinely grown on tryptone soya 
agar (TSA) or in tryptone soya broth (TSB) liquid cultures, 
and incubated at 37 °C. Antibiotic production was induced by 
growing strains on a minimal salts medium with glycerol as 
the sole carbon source (designated basal salts medium with 
glycerol; BSM- G) as previously described [25, 26].
Antimicrobial antagonism assays were performed by over-
laying with the following susceptibility testing organisms: 
Staphylococcus aureus ATCC 25923, Ralstonia mannitolilytica 
LMG 6866 and Candida albicans SC 5314, as previously 
described [25]. Escherichia coli strain NCTC 12241 was used 
as a control for the mushroom and onion rot assays. Artificial 
CF sputum medium was made up as previously described 
[27] to model whether bongkrekic acid production occurred 
under CF lung infection- like growth conditions. Trimetho-
prim (1 µg ml−1) was incorporated into BSM- G to determine 
whether B. gladioli metabolite production was induced by 
sub- inhibitory concentrations of this antibiotic, as described 
for Burkholderia thailandensis [28].
Genome sequencing, assembly and analysis
Genomic DNA was prepared from 3 ml TSB overnight 
cultures of B. gladioli. Cells were harvested by centrifugation 
and suspended in 400 µl of 4 M guanidine isothiocyanate 
solution (Invitrogen, UK). DNA was extracted from these 
bacterial suspensions using a Maxwell 16 automated nucleic 
acid purification system and the Maxwell tissue DNA purifica-
tion kit following the manufacturer’s instructions (Promega, 
UK). Purified DNA extracts were treated with RNase (New 
England BioLabs, UK). Genomes were sequenced using 
the Illumina HiSeq 2000 and HiSeq X Ten platforms at the 
Wellcome Sanger Institute as previously described [22]. 
Genomes were assembled from the read data, and anno-
tated and compared using a virtual machine hosted by the 
Cloud Infrastructure for Microbial Bioinformatics (CLIMB) 
consortium [29]. Sequence reads were trimmed using Trim 
Galore v0.4.2 (Babraham Bioinformatics), overlapped using 
FLASH v1.2.11 [30], and assembled using SPAdes v3.9.1 [31]. 
Assembled genomes were polished using Pilon v1.21 [32]. 
Prokka v1.12 beta [33] was used for gene prediction and 
annotation. The quality of genome assemblies was assessed 
using Quast and Prokka annotations cross- compared with 
gene predictions generated by Glimmer v3.02b [34]. Draft 
genome contigs were ordered against a complete reference 
genome for B. gladioli BCC0238 [21] using CONTUGuator 
v2.7 [35]. To supplement the Illumina sequencing, contigu-
ated genomes were generated for clade- specific strains 
BCC1710, BCC1621 and BCC1622 (see Table S1) using 
Pacific Biosciences single- molecule real- time sequencing as 
described previously [21].
Average nucleotide identity (ANI) was used for genomic 
taxonomy and calculated using PyANI v0.2.1 [36]. The 
B. gladioli core genome was computed using Roary v3.6.0 
[37]. Maximum- likelihood trees were drawn from the core 
gene alignment with FastTree [38] using the generalized time- 
reversible model of nucleotide evolution and visualized using 
FigTree (http:// tree. bio. ed. ac. uk/ software/ figtree). Rooting 
the trees with multiple Burkholderiales species (Burkholderia 
glumae, Burkholderia oklahomiensis and Paraburkholderia 
xenovorans) failed to produce a biologically meaningful root. 
The closest sequences to these outgroups were variable, but 
all produced trees of consistent phylogenetic separation for 
the B. gladioli clades identified. Therefore, an unrooted tree 
was presented in the final analysis. B. gladioli multilocus 
sequencing typing (MLST) sequence type (ST) assignments 
were made by using the PubMLST database and website 
[39], via the MLST tool developed by Torsten Seemann 
(https:// github. com/ tseemann/ mlst). Putative specialized 
metabolite BGCs in B. gladioli genomes were identified 
using antiSMASH v3 [40, 41] running as a local instance 
on CLIMB. The presence or absence of known BGCs was 
determined by mapping sequencing reads to representative 
BCG reference sequences using snippy (https:// github. com/ 
tseemann/ snippy). The percentage of reads mapping to the 
reference sequence, and the actual number of corresponding 
reads were used to manually determine the status of each 
BGC in a given strain.
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Mushroom and onion rot bioassays
Mushroom (Agaricus bisporus) soft- rot bioassays were carried 
out as described previously [42] with the surface sterilization 
and immersion into ice- cold water step omitted because this 
caused non- specific rotting of mushrooms. Briefly, mush-
rooms (Oakland closed cup mushroom, Lidl UK GmbH, 
produced in Ireland) were cut into 3–4 mm slices with a 
sterile blade. B. gladioli was grown overnight in TSB and the 
cap of each mushroom was inoculated with a 10 µl drop of 
bacterial suspension adjusted to 0.1 OD600 nm in TSB. Onion 
(Allium cepa) soft- rot bioassays were carried out as described 
previously [43]. Brown onions (Tesco, Cardiff, UK) had their 
skin and outer onion layer removed prior to quartering 
with a sterile knife. Individual onion layers were cut into 
3 to 4 cm pieces and wounded on their inner surface with 
a knife slit made under aseptic conditions, and the wound 
was inoculated with 10 µl of bacterial suspension produced 
as described for the mushroom assay. All assays (the test 
B. gladioli, a control E. coli NCTC 12241 strain, a TSB control 
and untreated controls) were performed in triplicate on sterile 
wet filter paper contained in sterile 9 cm plastic Petri dishes, 
sealed with Parafilm M and incubated at 30 °C for 48 h.
Preparation of B. gladioli metabolite extracts and 
antimicrobial activity
To analyse the metabolites produced by different B. gladioli 
strains, BSM- G agar plates (five per strain) were streaked with 
cells from a freshly revived culture and incubated for 72 h at 
30 °C. Biomass was removed using a sterile cell scraper and 
the spent agar was transferred to a glass bottle. Metabolites 
were extracted from the agar using dichloromethane (2 h 
with gentle shaking). The crude extract was concentrated to 
dryness under a vacuum at 22 °C and resuspended in 1 ml of 
dichloromethane. The bioactivity of each extract and control 
dichloromethane was tested by pipetting 5 µl onto a TSA plate 
and allowing the plates to dry and solvent to evaporate. Each 
plate was then overlaid with molten Iso- Sensitest agar (Oxoid, 
UK) seeded with S. aureus, R. mannitolilytica or C. albicans 
as described elsewhere [25]. Plates were incubated at 37 °C 
for 24 h and photographed to document zones of clearing. 
Bioactivity assays were performed in triplicate for each strain.
Analysis of B. gladioli metabolites by high-
performance liquid chromatography (HPLC)
HPLC analysis was used to quantify and identify known 
B. gladioli metabolites as follows. Specialized metabolites were 
produced by growing on BSM- G medium (as above) and 
extracted directly from a 20 mm agar disc cut from the plates 
as described elsewhere [44]. Extracts (20 µl injection volume) 
were analysed on a Waters AutoPurification HPLC System 
fitted with a reverse- phase analytical column (Waters XSelect 
CSH C18, 4.6×100 mm, 5 µm) and a C18 SecurityGuard 
cartridge (Phenomenex) in series. Absorbance at 210–400 nm 
was monitored using a photo diode array (PDA) detector. 
Mobile phases consisted of (a) water with 0.1 % formic acid 
and (b) acetonitrile with 0.1 % formic acid. A flow rate of 
1.5 ml min−1 was used. Elution conditions were as follows. 
0–1 min: 95 % (a)/5 % (b); 1–9 min: gradient of (a) from 
95–5 %/gradient of (b) from 5–95 %; 10–11 min: 5 % (a)/95 % 
(b); 11–15 min: 95 % (a)/5 % (b). Peak height and area were 
calculated using MassLynx V4.1 software ( www. waters. com).
To enable BGC- specialized metabolite correlations, a 
B. gladioli gene mutant unable to produced gladiolin [21] was 
used. B. gladioli toxoflavin, bongkrekic acid and caryoynencin 
non- producing mutants were constructed as follows. PCR 
products encoding fragments of core biosynthetic genes were 
amplified using specific primers (see Table S2) and cloned 
into the pGpΩTp suicide plasmid [45] following digestion 
with XbaI/EcoRI (bonA and cayA), or XbaI/KpnI (toxA). 
Plasmids were mobilized as described elsewhere[21] into 
B. gladioli BCC0238 to inactivate the gladiolin and toxoflavin 
BGCs, strain BCC1710 for the bongkrekic acid BGC and 
strain BCC1697 to disrupt the caryoynencin BGC. Compara-
tive HPLC analysis of metabolite extracts from parental and 
mutant strains, combined with high- resolution liquid chro-
matography mass spectrometry (LC- MS) analysis (see below), 
was used to identify BGC products.
High-resolution LC-MS of B. gladioli metabolite 
production
Known Burkholderia metabolites were confirmed by 
high- resolution LC- MS essentially as described elsewhere 
[19, 21, 22, 25]. Briefly, all B. gladioli strains were grown at 
30 °C on BSM- G agar. Single plates were extracted by removal 
of the biomass, chopping of the agar and extraction with 4 ml 
of ethyl acetate for 2 h. Centrifugation in a 1.5 ml Eppendorf 
tube was used to remove debris. Crude extracts were analysed 
directly by Ultra- highperformance liquid chromatography 
coupled with electrosprayionization- quadrupole- time of 
flight- mass spectrometry (UHPLC- ESI- Q- TOF- MS) analyses 
using a Dionex UltiMate 3000 UHPLC connected to a Zorbax 
Eclipse Plus C-18 column (100×2.1 mm, 1.8 µm) coupled to a 
Bruker MaXis II mass spectrometer. Mobile phases consisted 
of water (a) and acetonitrile (b), each supplemented with 0.1 % 
formic acid. A gradient of 5 % (b) to 100 % (b) over 30 min 
was used at a flow rate of 0.2 ml min−1. The mass spectrometer 
was operated in either positive or negative ion mode with a 
scan range of 50–3000 m/z. Source conditions were: end- plate 
offset at −500 V, capillary at −4500 V, nebulizer gas (N2) at 1.6 
bar, dry gas (N2) at 8 l min
−1 and dry temperature at 180 °C. 
Ion transfer conditions were: ion funnel radio frequency (RF) 
at 200 Vpp, multiple RF at 200 Vpp, quadrupole low mass at 
55 m/z, collision energy at 5.0 eV, collision RF at 600 Vpp, ion 
cooler RF at 50–350 Vpp, transfer time at 121 μs and pre- pulse 
storage time at 1 μs. Calibration was performed with 1 mM 
sodium formate through a loop injection of 20 µl at the start 
of each run.
To analyse bongkrekic acid production in artificial CF sputum 
medium [27], 50 ml cultures of B. gladioli were grown for 
3 days and centrifuged to remove bacterial cells, after which 
the supernatant was passed through a 2 µm filter to remove 
all cells and sterilize. The filtrate then passed through Sep- 
Pak C18 Vac Cartridge (500 mg), washed with two column 
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volumes of water and finally eluted with 6 ml of methanol. 
The methanol was concentrated to 500 µl for bongkrekic acid 
detection by high- resolution LC- MS as above.
PCR detection of the bongkrekic acid BGC
To detect the presence of the bongkrekic acid BGC, PCR 
probes were designed to target the central polyketide 
synthase gene, bonA, in the gene cluster from B. gladioli 
BCC1710 (bonA- F, 5′- ATTT CTAG AAGT ATCC GCAT TTTC 
GTCGC-3′; bonA- R 5′- TATG AATT CGAT CGAT CAGT 
TGCG CTTCC-3′). PCRs were performed using the Taq PCR 
Core kit (Qiagen) as per the manufacturer’s instructions and 
incorporating Q- solution.
The thermal cycling conditions comprised an annealing 
temperature of 54.5 °C and an extension time of 1 min 5 s, 
run over 30 cycles. The 1053 bp amplicon internal to bonA 
was detected by gel electrophoresis. The amplicon from the 
BCC1710 strain was subjected to Sanger sequencing (Euro-
fins, Genomics) to confirm its identity.
Accession numbers
The sequence read data from the B. gladioli isolates examined 
in this study are available from the European Nucleotide 
Archive under the project accession numbers PRJEB9765 and 
PRJEB35318 [46]; isolate accession numbers are provided in 
Table S1.
RESULTS
Assembly and genomic taxonomy of a B. gladioli 
isolate collection
To provide a holistic understanding of taxonomy and 
pathovar population biology of B. gladioli, a representative 
collection of 206 isolates was assembled and their genomes 
sequenced (Table S1). The majority of isolates (n=194) were 
from people with CF, with 181 from the USA, 7 from the 
UK, 4 from Canada, and 1 each from Australia and Italy 
(Table S1). Twelve strains were from environmental sources 
including pathovar reference isolates as follows: isolates of 
plant disease- associated B. gladioli pv. gladioli (n=3), pv. 
agaricicola (n=3) and pv. alliicola (n=3), and B. gladioli pv. 
cocovenenans (n=2) toxin- producing strains. One B. gladioli 
isolated from an environmental industrial source was also 
included (BCC1317; Table S1). Short- read sequencing yielded 
high- quality draft genome sequences [average of 82 contigs, 
ranging from 20 (BCC1721) to 284 (BCC1788)] with a mean 
size for B. gladioli of 8.28 Mb. The mean GC content was 68 % 
and the genomes contained a mean of 6872 protein- encoding 
genes (Table 1). These metrics were consistent with previously 
reported B. gladioli genomes [21, 23, 24].
Since the assignment of isolates within the genus Burkholderia 
[4] generally, and B. gladioli specifically [7, 9], has undergone 
multiple rounds of taxonomic reclassification, we initially 
established whether the 206 B. gladioli isolates in the collection 
comprised a single bacterial species. Using average nucleotide 
identity, the 96.85 % ANI for the entire B. gladioli 206 genome 
dataset was above the 95 % cut- off used in genomic taxonomy 
for designation as a single species [47]. This confirmed that 
the previous incorporation of B. cocovenenans (strains LMG 
11626 and LMG 18113) [7] and P. marginata (ATCC10248) 
[8] into B. gladioli is supported by the genomic taxonomy 
(Table S1) [47].
ANI heatmap analysis also suggested that a significant subspe-
cies population structure existed within B. gladioli (Fig. 1), 
and as such the following designation of groups was made. 
Group 1 (n=27) comprised three closely related sub- groups: 
1A, containing the reference B. gladioli pv. cocovenenans 
strains, 1B and 1C; each subgroup was distinct in terms of 
their ANI relatedness (Fig. 1). All isolates within each 1A, 
1B and 1C subgroup contained the bongkrekic acid BGC 
(see below; Table S1), setting them apart from the rest of the 
B. gladioli collection, and supporting their collective designa-
tion as group 1. Group 2 was composed of 73 strains and 
included all 3 B. gladioli pv. allicola reference isolates. Group 
3 (n=106) contained both the B. gladioli pv. agaricicola and 
B. gladioli pv. gladioli reference isolates (Fig. 1). Within each 
of these three initial groupings, the genomic ANI ranged from 
>98.1 % (group 3) to >99.1 % (group 1B), which was greater 
than the 96.85 % collection average and suggested that distinct 
genetic lineages were present within B. gladioli (Fig. 1).
Core gene phylogenomic analysis reveals distinct 
evolutionary clades within B. gladioli
To investigate the evolutionary linkages behind the ANI 
groupings (Fig.  1), we constructed a phylogeny from the 
4406 core genes identified within the 206 B. gladioli genome 
dataset. The strain groups defined by ANI (Fig. 1) were also 
supported as distinct clades in the phylogenomic analysis 
(Fig.  2). The three group 1 ANI sub- clusters correspond-
ingly separated as clades 1A, 1B and 1C, with the reference 
B. gladioli pv. cocovenenans strains locating specifically 
to clade 1A (Fig. 2). These group 1 strains separated as 13 
isolates in clade 1A, 4 in clade 1B and 10 in clade 1C (Table 
S1). At the distal ends of the B. gladioli phylogenetic tree 
were clade 2 and clade 3 strains (Fig. 2), which corresponds 
to the respective ANI groupings (Fig. 1). All three reference 
B. gladioli pv. allicola strains mapped to clade 2, indicating 
that the pathovar status is evolutionarily supported. However, 
B. gladioli pv. agaricicola and pv. gladioli grouped within 
clade 3 and were not genetically distinguished (except that 
they were distinct from clades 1 and 2; Fig. 2). Core gene 
Table 1. Summary genome sequencing statistics (n=206)
  Mean Maximum Minimum
No. of 
contigs
82.6 284 (BCC1788) 20 (BCC1721)
Genome size 8.28 Mb 8.94 Mb (BCC1815) 7.32 Mb (BCC1681)
N50 404 821 1 964 774 (BCC1691) 147 146 (BCC1713)
%GC 68.0 % 68.31 % (BCC1823) 67.39 % (BCC1815)
No. of genes 6872 7693 6012
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content did not vary extensively across the phylogenomic 
lineages, ranging from 4682 for group 2 to 5109 for group 
3 B. gladioli, with the group 1 genomes encoding 4847 core 
genes (Table S3). The significance of core gene differences 
between the lineage remains to be determined, but a defining 
conserved feature of the group 1 genomes was the presence 
of the bongkrekic acid BGC.
Ecological and disease associations of B. gladioli 
evolutionary clades
Given the evolutionary support for the clade restriction of 
B. gladioli pv. allicola, and grouping of pv. gladioli and pv. 
agaricicola strains in a separate clade (Fig. 2), the ability of 
selected B. gladioli strains to rot eukaryotic tissues was inves-
tigated. Mushroom soft- rot bioassays [42] demonstrated 
that B. gladioli strains from all three phylogenomic groups 
were capable of decaying mushroom tissue (Fig. 3). The assay 
confirmed the ability of the pv. agaricicola reference strain 
NCPPB 3852 (BCC1883; Fig. 3k) to cause disease in its origi-
nally associated host. The degree of mushroom rot observed 
varied, with severe degradation of the mushroom cap tissue 
most apparent in clade 2 and 3 strains, compared with clade 1 
producing less extensive rot (Fig. 3). The pathovar agaricicola- 
like strains therefore did not appear to be specifically adapted 
to degrade mushroom tissue. B. gladioli from all three clades 
also showed conserved plant tissue degradation capabili-
ties within an onion soft- rot model [43]. A variable onion 
rot phenotype was observed for each strain, with the most 
extensive tissue pitting seen in clades 2 and clade 3 (Fig. S1). 
Overall, rotting capability was demonstrated by the B. gladioli 
strains from all genetic groups.
Fig. 1. B. gladioli comprises a single genomic species with evidence of 
subspecies clustering by average nucleotide identity. The ANI of 206 
B. gladioli genomes was compared using pyANI and a heatmap was 
constructed (see the Methods section). Darker red shading correlates 
to the greater percentage identity of each isolate. Sub- groups with 
greater than 98.8 % ANI are shown within the black outlined boxes. The 
main clusters are labelled as group 1, 2 and 3, with group 1 isolates 
sub- dividing further into sub- groups 1A, 1B and 1C (see top right). Four 
non-B. gladioli species genomes were used as taxonomic controls: 
three strains of the closely related species B. glumae and one strain 
of B. ambifaria; their low nucleotide identity to B. gladioli (ANI <95 %) is 
shown in blue.
Fig. 2. The population biology of B. gladioli inferred by core genome gene phylogeny. The core genome of the 206 B. gladioli strains 
were analysed using Roary and the resulting 4406 core genes were aligned and used to construct a phylogeny. A maximum- likelihood 
unrooted tree was constructed using the generalized time- reversible model of nucleotide evolution; multiple rooting with species outside 
of B. gladioli was used to confirm topology (see the Methods section). The approximate positions of the environmental B. gladioli pathovar 
reference strains are shown (green font), together with representative CF isolates (purple font) and the country of origin for each isolate. 
The position of the model gladiolin- producing strain, BCC0238, is indicated by * (see group 3). The five major evolutionary branches 
consistent with the ANI groups and sub- groups are numbered accordingly. Clades 1A,1B and 1C all contained the bongkrekic acid BGC 
and are collectively designated as group 1 B. gladioli (see brackets). The scale bar represents the number of base substitutions per site.
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Since 94 % of the 206 B. gladioli strain collection derived 
from CF lung infections (Table S1), this disease source was 
also the major origin for each of the clades, demonstrating 
that opportunistic human pathogenicity was also a shared 
species phenotype (Fig. 2). For the 181 CF strains originating 
from the USA, mapping the state location of the submitting 
CF treatment centre showed that B. gladioli infections were 
geographically widespread with no phylogeographic linkages 
to clade types (Fig. S2). The group 1 B. gladioli strains (Figs 1 
and 2), which possess the ability to produce bongkrekic acid 
(see below), were also found to be capable of causing CF lung 
infections, linking them to opportunistic lung disease for the 
first time.
B. gladioli possess broad antimicrobial bioactivity
B. gladioli is known to produce an array of bioactive special-
ized metabolites, including toxoflavin [16], bongkrekic acid 
[14], enacyloxins [17], caryoynencin [48], sinapigladioside 
[20], gladiolin [21] and icosalides [18, 19]. Given this wealth 
of bioactive products, two B. gladioli strains representative 
of each clade within the species population biology (Fig. 2) 
were screened for antimicrobial activity. Metabolite extracts 
from the spent agar of B. gladioli cultures were examined for 
activity against Gram- positive and Gram- negative bacteria, 
and fungi. All 10 strains tested demonstrated activity against 
S. aureus. Only the two isolates from B. gladioli clade 1C 
lacked antifungal activity, while the extracts from the 
B. gladioli clade 1C, clade 2 and clade 3 strains possessed 
activity against Gram- negative bacteria (Fig. 4a). Overall, this 
analysis demonstrated that all the B. gladioli strains secreted 
extractable bioactive compounds, but the quantity and spec-
trum of activity varies (Fig. 4a).
To determine which metabolites accounted for the 
B. gladioli bioactivity (Fig. 4b), a combination of HPLC, high- 
resolution LC- MS (Fig. S3) and BGC pathway mutagenesis 
was employed. Under growth conditions that are known to 
promote specialized metabolite biosynthesis [25], toxoflavin 
was produced by all B. gladioli strains tested (Figs 4b and 
S3a). The isothiocyanate sinapigladioside [20] was produced 
by both clade 1C strains and one clade 3 strain (Fig. S3f). 
Enacyloxin IIa [25] was present in both clade 1A strains, a 
clade 1C strain and a clade 3 strain, and was also detected at 
low quantities within the clade 2 strain BCC1848 (Figs 4b and 
S3b). Production of the polyyne caryoynencin [48] (Fig. S3g) 
was widespread. It was detected in 8 of the 10 strains tested, 
and was only absent from clade 1C strains (Fig. 4b). Gladiolin 
[21] was detected in the B. gladioli BCC0238 strain it was 
originally discovered from (Fig. S3e), but was absent from the 
other strains examined (Fig. 4b). Bongkrekic acid (Fig. S3c) 
was detected in all six clade 1 strains, although only limited 
amounts were present in the two clade 1B strains examined 
(Fig. 4b). Overall, the metabolite analysis showed that indi-
vidual B. gladioli strains were capable of producing up to four 
different bioactive metabolites (Fig. 4b), underpinning the 
broad- spectrum antimicrobial activity of B. gladioli (Fig. 4a).
Distribution of known specialized metabolite BGCs 
in B. gladioli
To characterize the genetic basis for the observed bioactivity 
and metabolite production profiles (Fig. 4), the distribution 
of specialized metabolite BGC was investigated within the 
B. gladioli genome collection. Using sequence read mapping 
to B. gladioli BGCs for known metabolites enabled toxoflavin, 
caryoynencin, bongrekic acid, enacyloxin, gladiolin and 
icosalide BGCs to be mapped. Across the phylogenomically 
defined B. gladioli clades, random distribution of BGCs was 
observed in some cases, whereas other BGCs were found to 
Fig. 3. B. gladioli from all evolutionary clades are capable of mushroom 
rot. The ability of B. gladioli strains to degrade mushroom tissue 
was tested by inoculating commercial mushroom tissue slices 
with standardized bacterial cultures. Inoculated mushrooms were 
incubated at 30 °C for 48 h with the following shown in each panel 
(each row are either controls or B. gladioli clades as indicated on the 
left): (a) no- treatment control, (b) TSB only, (c) E. coli NCTC 12241, 
(d) B. gladioli clade 1A strain BCC1710, (e) clade 1B strain BCC1675, 
(f) clade 1C strain BCC1678, (g) B. gladioli clade 2 strain BCC1731, 
(h) B. gladioli pv. allicola reference clade 2 strain BCC1645, (i) B. gladioli 
pv. allicola reference clade 2 strain BCC1646, (j) B. gladioli clade 3 strain 
BCC0238, (k) B. gladioli pv. agaricola reference clade 3 strain BCC1883 
(NCPPB 3852), (l) B. gladioli pv. gladioli reference clade 3 strain BCC771 
(LMG 2216T). Pitting and tissue degradation was apparent in all 
B. gladioli- inoculated mushrooms; a scale bar (1 cm) is shown in each 
panel to enable comparison.
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be clade- specific (Fig. 5a). The toxoflavin, caryoynencin and 
icosalide BGCs were widely distributed across B. gladioli, 
with the toxoflavin BGC being absent from only 2 of the 206 
strains. The caryoynencin BGC was uniquely absent from all 
10 clade 1C strains (correlating to a lack of detection of the 
metabolite; Fig. 4b). The icosalide BGC mirrored this clade 
1C absence, but also showed random loss in six other strains 
from across B. gladioli (one clade 1B, four clade 2 and one 
clade 3 strain; Fig. 5a). The gladiolin and bongkrekic BGCs 
demonstrated evolutionary restrictions to specific clades as 
follows. A total of 83 of the 106 clade 3 strains (78%) contained 
the gladiolin BGC and it was absent from all other B. gladioli 
clades. All 27 strains within clades 1A, 1B and 1C contained 
the bongkrekic acid BGC, validating its presence as a marker 
that collectively designates them as group 1 strains (Fig. 1), 
despite their distinct nature as evolutionary clades (Fig. 2).
The enacyloxin BGC was randomly distributed across 
B. gladioli (Fig. 5a). Its presence in clade 1 strains was most 
conserved with 21 of 27 strains (77 %) and 100 % of clade 1C 
strains contained the BGC. Interestingly, no strain within the 
collection of 206 contained both the enacyloxin and gladiolin 
BGCs (Fig. 5a). Genomic interrogation of this inverse correla-
tion led to the discovery that these large polyketide BGCs 
Fig. 4. B. gladioli antimicrobial activity and bioactive metabolite analysis. (a) The bioactivity of metabolites extracts made from spent 
growth media from B. gladioli cultures. The bioactivity from equivalent metabolite extracts of strains representative of each clade are 
shown as follows (clade and BCC number are labelled): B. gladioli Clade 1A strains BCC1710 and BCC1880, Clade 1B strains BCC1675 
and BCC1735, and Clade 1C strains BCC1678 and 1871; B. gladioli Clade 2 strains BCC1770 and BCC1848 and B. gladioli Clade 3 strains 
BCC0238 and B. gladioli pv. agaricicola reference Clade 3 strain BCC1883 (NCPPB 3852). Each area of bioactivity was cropped to scale 
and represents a 3 cm section of the inoculated petri dish. Zones of growth inhibition against C. albicans (CA), R. mannitolilytica (RM) 
and S. aureus (SA) are labelled as rows. (b) The quantitative analysis of known B. gladioli metabolites present in the metabolite extracts 
as determined by HPLC. Each circle is proportionally scaled to the mean peak height for the following metabolites: toxoflavin (TF), 
sinapigladioside (SG), enacyloxin IIa (EC), caryoynencin (CN), gladiolin (GL) and bongkrekic acid (BA).
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occupied the same genetic locus in B. gladioli (Fig. 5b). This 
conserved region of the genome is on the second genomic 
replicon of B. gladioli and contains either enacyloxin (43 
strains), gladiolin (83 strains), or no specialized metabo-
lite (80 strains) BGCs. Upstream and downstream of this 
polyketide BGC insertion point were blocks of conserved and 
syntenic genomic DNA. These surrounding regions of the 
B. gladioli second genomic replicon did not contain mobile 
DNA markers, indicating the BGC insertion point as a gene 
capture hotspot.
B. gladioli bongkrekic acid biosynthesis: a new 
potential risk factor for CF lung infection
In total, 25 of the 27 strains in clades 1A, 1B and 1C were recov-
ered from lung infections in people with CF (Table S1, Fig. 2), 
and all possess the bongkrekic acid BGC (Fig. 5a). To date this 
lethal toxin has only been associated with B. gladioli- related 
food poisoning [13, 14, 49], and has not been linked to disease 
in people with CF. Analysis of 12 toxin BGC- positive strains 
showed that 11 of them produced bongkrekic acid in vitro, but 
to varying extents (Fig. S4). Four of these B. gladioli strains 
(BCC1675, BCC1686, BCC1701 and BCC1710; Fig. S4) were 
subsequently grown in artificial CF sputum medium [27], and 
with the exception of strain BCC1701 (a low toxin producer; 
Fig. S4), toxin production was detected by high- resolution 
LC- MS. This observation prompted the development of a 
diagnostic PCR to enable rapid identification of B. gladioli 
isolates containing the bongkrekic acid BGC, as a potential 
clinical risk marker for CF. Application of this PCR (Fig. S5) 
to 122 B. gladioli CF isolates prior to their genome sequencing 
identified 13 positives. Subsequent genome sequencing 
demonstrated that all contained a complete bongkrekic acid 
BGC (Fig. 5a), validating the approach.
Since CF patients are administered multiple antibiotics to suppress 
lung infections, a recent report that low concentrations of antibiotics 
may induce specialized metabolite production in Burkholderia [50] 
further highlighted the potential risk of bongkrekic acid- producing 
B. gladioli strains to CF patients. Furthermore, the antibiotic 
trimethoprim, which is widely used for treatment of Burkholderia 
infections in CF, was shown to be an effective elicitor of specialized 
metabolite production in B. thailandensis [28], compounding the 
threat of strains containing the bongkrekic acid BGC. To examine 
whether trimethoprim induced expression of the bongkrekic acid 
BGC, six B. gladioli strains isolated from CF patients that produced 
bongkrekic acid at a range of titres (Fig. 6a) were investigated to 
determine whether sub- inhibitory levels of the antibiotic increased 
toxin biosynthesis. In contrast to B. thailandensis [28], no B. gladioli 
strains demonstrated induction of bongkrekic acid upon exposure 
to trimethoprim. Instead, toxin production was suppressed in five 
of the six strains analysed (B. gladioli BCC1678; Figs 6b, c and S6 
show the data for all six strains tested).
Fig. 5. Distribution of known B. gladioli specialized metabolite BGCs and common genomic location for gladiolin and enacyloxin 
biosynthesis. (a) Sequence reads were mapped to known specialized metabolite BGCs to determine their presence or absence within the 
206 the B. gladioli genomes. BGC presence indicated by red shading and columns from left to right show the B. gladioli clade, and BGCs 
for toxoflavin, caryoynencin, bongkrekic acid, gladiolin, enacyloxin IIa and icosalide. (b) A genomic comparison plot was constructed 
using the Artemis Comparison Tool for B. gladioli BCC0238 (clade 3) and BCC1710 (clade 1A). The common insertion point for either 
the gladiolin or enacyloxin BGCs in these strains is shown, together with extensive genomic synteny upstream and downstream of this 
specialized metabolite- encoding location (scale bar indicates 58.4 kb).
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DISCUSSION
In the last decade, the specialized metabolites produced by 
Burkholderia have been studied extensively and multiple 
compounds have been shown to be functional in different 
ecological settings [15]. B. gladioli shows a very wide 
range of beneficial [9, 20, 21] versus detrimental traits 
[7, 8, 13, 49, 51], several of which relate to specialized 
metabolite production. With multiple taxonomic reclassifi-
cations [7, 9], an unknown basis for pathovar status in plant 
disease [7, 8, 11], calls for a specific recognition of the lethal 
Fig. 6. Sub- inhibitory concentrations of trimethoprim reduce bongkrekic acid production by B. gladioli clade 1 strains. (a) HPLC analysis of 
6 B. gladioli strains (strain numbers are shown) belonging to clades 1A, 1B and 1C demonstrated variable levels of bongkrekic acid toxin 
production by HPLC analysis of their metabolite extracts (peak height is plotted). Differences between the mean values of bongkrekic 
acid were determined using the LSD test α=0.05. Means followed by the same letter are not significantly different. (b) The presence 
of sub- inhibitory concentrations of trimethoprim (1 µg ml−1) reduced the production of bongkrekic acid in strain BCC1678, as shown by 
the HPLC metabolite analysis comparing production levels against the control condition without antibiotic. (c) Quantitative comparison 
of bongkrekic acid production by strain BCC1678 in the presence and absence of trimethoprim (n=9) shows the significant (P<0.001) 
suppression of toxin biosynthesis caused by antibiotic exposure. Statistical significance was determined using a two- tailed t- test.
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food- poisoning cocovenenans pathovar [13], an emerging 
presence in CF lung infection [2] and an expanding role 
as a source of specialized metabolites [15, 17–19, 21, 48], 
there is a clear need to better understand the population 
ecology of B. gladioli.
The population biology and pathogenicity traits of very few 
Burkholderia species have been described in depth using 
phylogenomics. The transmission dynamics of a Burkholderia 
dolosa CF outbreak was tracked in 14 patients over 16 years 
and identified mutations in the 112 isolates that showed 
parallel evolution towards increased antibiotic resistance 
and tolerance of low oxygen [52]. The cause of melioidosis, 
Burkholderia pseudomallei, has been subjected to arguably 
the most extensive genomic characterization because of its 
pathogenicity and due to its threat as a bioterrorism agent 
[53]. Genome sequencing of 469 B. pseudomallei isolates 
showed the species comprised 2 distinct populations, an 
ancestral Australian reservoir that anthropogenically trans-
mitted and diverged within Asia, and spread further via the 
slave trade from Africa to South America [53]. Mapping the 
phylogenomics of B. ambifaria as a historically used biopesti-
cide identified cepacin as a key antimicrobial mediating plant 
protection against pathogenic oomycetes [22]. However, the 
population biology of plant pathogenic Burkholderia has 
not been studied and our genomic analysis of B. gladioli is 
unique in uncovering whether plant pathovar status has an 
evolutionary basis. Only the B. gladioli pv. allicola associ-
ated with onion soft- rot plant disease were evolutionarily 
distinct as clade 2 strains (Fig. 2), but rotting capability was 
associated with all clades and historical pathovars (Figs 3 and 
S1). The specific genetic factors linked to the separation of 
pathovar allicola as clade 2 and its distinction from clade 3 
plant disease strains remain to be determined.
In contrast to the broad conservation of plant disease 
traits across B. gladioli, bongkrekic acid- producing strains 
[13, 14, 49] associated with fatal human food poisoning 
were more closely related. They were designated group 1 by 
their ANI relatedness (Fig. 1) and the conserved presence 
of the bongkrekic acid BGC in these strains adds weight 
to the call for their differentiation as a toxin- producing 
B. gladioli subgroup [13]. With 13 % of the B. gladioli CF 
isolates examined containing the bongkrekic acid BGC, 
toxin production is a worrying potential risk factor for 
CF lung infections, especially as this can occur under 
lung infection- like growth conditions, such as artificial 
CF sputum. The clinical outcome of Burkholderia infec-
tion is frequently highly variable [54] and severe systemic 
disease has been associated with B. gladioli in CF [5]. With 
the ability to rapidly identify bongkrekic acid- positive 
B. gladioli isolates using a PCR diagnostic (Fig. S5), we 
are now in a strong position to understand whether the 
toxin plays a role in poor clinical outcome for infected CF 
patients. Also, since we have shown that trimethoprim acts 
to suppress toxin production (Fig. 6), rather than activate it 
[27, 28], a case can be made for therapy with the antibiotic 
to be maintained in bongkrekic acid- positive B. gladioli CF 
infections.
By combining genomics with analytical chemistry, we have 
also been able to map the repertoire of bioactive special-
ized metabolite BGCs across the B. gladioli species. This 
demonstrated that the bioactivity of B. gladioli frequently 
results from the production of multiple metabolites (Fig. 4). 
The widespread distribution and conservation of BGCs 
for toxoflavin [16], caryoynencin [48] and the icosalides 
[18, 19] suggest that they are ancestral to B. gladioli as a 
species (Fig. 5). The confinement of the gladiolin BGC to 
clade 3 strains also sheds light on the classification of the 
recently identified B. gladioli symbiont strain that protected 
the eggs of Lagriinae beetles from fungal attack [20]. The 
beetle symbiont, B. gladioli Lv- StA, contains the gladiolin 
BGC [21] and has been reported to produce lagriene [20], 
also known as iso- gladiolin, which results from rearrange-
ment of gladiolin during isolation [21]. Since the gladiolin 
BGC is restricted to B. gladioli clade 3, the characterized 
insect symbiont [20] must be a member of this clade. 
Whether other evolutionary groups within B. gladioli also 
form these close associations with insects remains to be 
determined. It is also clear that all B. gladioli clades are 
geographically widely distributed from the analysis of US 
CF infection strains (Fig. S2). The ecological significance 
of herbivorous Lagriinae and other beetles in distributing 
the such bacterial symbionts across continental ranges will 
be fascinating to understand.
We were able to gain an insight into the ecological distri-
bution of B. gladioli by indirectly sampling the opportun-
istic infections the bacterium causes in people with CF. 
Although our B. gladioli collection was mainly derived 
from people with CF living in the USA (126 isolates; Table 
S1), the 206 genomes examined were genetically diverse 
and comprised 133 unique MLST sequence types (Table 
S1). In the absence of patient- to- patient or common source 
transmission, the natural environment is the main source 
of Burkholderia lung infections in CF patients [2]. From 
the US CF patient data, all B. gladioli clades appear widely 
distributed across the North American continental range 
(Fig. S2), with the majority being represented by geneti-
cally unique strains (Table S1). Soil, the rhizosphere and 
terrestrial freshwater environments are common sources 
of Burkholderia [3]. Outside of the infection of people with 
CF [2], plant disease [7, 8, 11] or food- poisoning [13], little 
is known about other sources of B. gladioli. Recent findings 
of close associations with insects [20] and fungi [18, 19] 
point to multiple symbiotic roles played by B. gladioli in the 
natural environment. By defining a systematic framework 
of population biology and metabolite production, a basis 
from which to understand the diverse ecology of B. gladioli 
is now in place.
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